tradingkey.logo
tradingkey.logo
Buscar

STAAR Surgical Co

STAA
Añadir a la lista de seguimiento
32.070USD
+0.060+0.19%
Cierre 05/15, 16:00ETCotizaciones retrasadas 15 min
1.59BCap. mercado
PérdidaP/E TTM

Más Datos de STAAR Surgical Co Compañía

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.

Información de STAAR Surgical Co

Símbolo de cotizaciónSTAA
Nombre de la empresaSTAAR Surgical Co
Fecha de salida a bolsaFeb 24, 1992
Director ejecutivoFarrell (Stephen C)
Número de empleados1157
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 24
Dirección1911 Walker Ave
CiudadMONROVIA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal91016
Teléfono16263037902
Sitio Webhttps://www.staar.com/
Símbolo de cotizaciónSTAA
Fecha de salida a bolsaFeb 24, 1992
Director ejecutivoFarrell (Stephen C)

Ejecutivos de STAAR Surgical Co

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Stephen C. (Steve) Farrell, CPA
Mr. Stephen C. (Steve) Farrell, CPA
Chief Executive Officer, Director
Chief Executive Officer, Director
82.21K
+57.24%
Mr. Wei Jiang
Mr. Wei Jiang
Director
Director
67.50K
--
Mr. Warren Foust
Mr. Warren Foust
President, Chief Operating Officer
President, Chief Operating Officer
53.33K
-6.47%
Mr. Nathaniel B. Sisitsky, Esq.
Mr. Nathaniel B. Sisitsky, Esq.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
30.18K
+72.87%
Dr. Magda Michna, Ph.D.
Dr. Magda Michna, Ph.D.
Chief Development Officer
Chief Development Officer
23.32K
-7.20%
Ms. Deborah J. Andrews
Ms. Deborah J. Andrews
Chief Financial Officer
Chief Financial Officer
8.59K
--
Dr. Elizabeth Yeu, M.D.
Dr. Elizabeth Yeu, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
5.10K
--
Mr. Louis E. (Lou) Silverman
Mr. Louis E. (Lou) Silverman
Independent Director
Independent Director
475.00
--
Mr. Brian Moore
Mr. Brian Moore
Vice President - Investor Relations and Corporate Development
Vice President - Investor Relations and Corporate Development
--
--
Ms. Lilian Zhou
Ms. Lilian Zhou
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Stephen C. (Steve) Farrell, CPA
Mr. Stephen C. (Steve) Farrell, CPA
Chief Executive Officer, Director
Chief Executive Officer, Director
82.21K
+57.24%
Mr. Wei Jiang
Mr. Wei Jiang
Director
Director
67.50K
--
Mr. Warren Foust
Mr. Warren Foust
President, Chief Operating Officer
President, Chief Operating Officer
53.33K
-6.47%
Mr. Nathaniel B. Sisitsky, Esq.
Mr. Nathaniel B. Sisitsky, Esq.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
30.18K
+72.87%
Dr. Magda Michna, Ph.D.
Dr. Magda Michna, Ph.D.
Chief Development Officer
Chief Development Officer
23.32K
-7.20%
Ms. Deborah J. Andrews
Ms. Deborah J. Andrews
Chief Financial Officer
Chief Financial Officer
8.59K
--

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de abr
Divisa: USDActualizado: lun., 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
Others
93.84M
39.19%
China
77.78M
32.48%
Japan
45.27M
18.90%
U. S.
22.56M
9.42%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.

Estadísticas de accionistas

Actualizado: jue., 14 de may
Actualizado: jue., 14 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Broadwood Capital, Inc.
32.38%
BlackRock Institutional Trust Company, N.A.
13.44%
Yunqi Capital Limited
6.54%
Madison Avenue Partners LP
5.73%
Magnetar Capital Partners LP
4.97%
Otro
36.94%
Accionistas
Accionistas
Proporción
Broadwood Capital, Inc.
32.38%
BlackRock Institutional Trust Company, N.A.
13.44%
Yunqi Capital Limited
6.54%
Madison Avenue Partners LP
5.73%
Magnetar Capital Partners LP
4.97%
Otro
36.94%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
53.68%
Investment Advisor
31.49%
Investment Advisor/Hedge Fund
21.11%
Research Firm
6.23%
Pension Fund
1.00%
Individual Investor
0.66%
Bank and Trust
0.36%
Venture Capital
0.06%
Insurance Company
0.02%

Participación institucional

Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
543
58.06M
116.62%
-10.58M
2025Q4
536
52.38M
105.30%
-16.01M
2025Q3
511
49.83M
100.45%
-14.96M
2025Q2
543
53.99M
109.59%
-5.64M
2025Q1
586
53.67M
108.47%
-5.73M
2024Q4
611
49.68M
100.75%
-8.34M
2024Q3
633
50.35M
102.36%
-6.37M
2024Q2
636
49.69M
101.15%
-10.70M
2024Q1
632
50.54M
103.45%
-9.24M
2023Q4
640
52.70M
107.96%
-9.84M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Broadwood Capital, Inc.
16.12M
32.56%
+670.21K
+4.34%
Mar 13, 2026
BlackRock Institutional Trust Company, N.A.
6.69M
13.51%
+107.78K
+1.64%
Dec 31, 2025
Yunqi Capital Limited
3.26M
6.58%
+750.00K
+29.91%
Jan 14, 2026
Magnetar Capital Partners LP
2.47M
4.99%
+1.27M
+105.28%
Dec 31, 2025
Goldman Sachs & Company, Inc.
1.97M
3.98%
+1.11M
+128.32%
Dec 31, 2025
State Street Investment Management (US)
1.94M
3.92%
+29.50K
+1.54%
Dec 31, 2025
Balyasny Asset Management LP
1.54M
3.11%
-272.35K
-15.02%
Dec 31, 2025
Ver más

ETFs relacionados

Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
AltShares Merger Arbitrage ETF
2.71%
ProShares Merger ETF
2.53%
State Street SPDR S&P Health Care Equipment ETF
1.67%
NYLI Merger Arbitrage ETF
0.87%
Invesco S&P SmallCap Health Care ETF
0.79%
Royce Quant Small-Cap Quality Value ETF
0.26%
State Street SPDR S&P SmallCap 600 ESG ETF
0.13%
iShares S&P Small-Cap 600 Growth ETF
0.1%
State Street SPDR S&P 600 Small Cap Growth ETF
0.1%
iShares ESG Select Screened S&P Small-Cap ETF
0.1%
Ver más
AltShares Merger Arbitrage ETF
Proporción2.71%
ProShares Merger ETF
Proporción2.53%
State Street SPDR S&P Health Care Equipment ETF
Proporción1.67%
NYLI Merger Arbitrage ETF
Proporción0.87%
Invesco S&P SmallCap Health Care ETF
Proporción0.79%
Royce Quant Small-Cap Quality Value ETF
Proporción0.26%
State Street SPDR S&P SmallCap 600 ESG ETF
Proporción0.13%
iShares S&P Small-Cap 600 Growth ETF
Proporción0.1%
State Street SPDR S&P 600 Small Cap Growth ETF
Proporción0.1%
iShares ESG Select Screened S&P Small-Cap ETF
Proporción0.1%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
KeyAI